Karyopharm Therapeutics Inc. reports developments tied to its commercial oncology business and selinexor-based drug development. The company markets XPOVIO (selinexor) and reports U.S. product revenue, license and other revenue, liquidity, and operating updates alongside its periodic financial results.
Recurring KPTI news also covers late-stage clinical programs evaluating selinexor in cancer indications, including the Phase 3 SENTRY trial in myelofibrosis and the Phase 3 XPORT-EC-042 trial in endometrial cancer. Company updates include clinical data presentations, regulatory-development disclosures, equity inducement grants under Nasdaq rules, financing activity, and other corporate and capital-structure matters.
On May 26, 2021, Karyopharm Therapeutics (Nasdaq: KPTI) announced that CEO Richard Paulson will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference. The event is scheduled for June 2, 2021, at 9:30 a.m. ET. A live webcast can be accessed through the Investor section of the company's website, with a replay available for 30 days post-event. Karyopharm focuses on pioneering novel cancer therapies, including its lead compound XPOVIO® (selinexor), approved for multiple hematologic malignancies in the U.S. and Europe.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the selection of sixteen abstracts for virtual presentation at the ASCO Annual Meeting from June 4-8, 2021. Key highlights include clinical data on XPOVIO® (selinexor) from pivotal studies, showcasing its efficacy in treating multiple myeloma and other cancers. The presentations feature subgroup analyses from the Phase 3 BOSTON study and updates from various combination studies, emphasizing the potential of XPOVIO in overcoming treatment resistance.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the grant of stock options for 55,300 shares to seven new employees as an inducement for joining the company. The options have an exercise price of $9.34, based on the stock's closing price on April 30, 2021. Each option vests over four years, with the first 25% vesting after one year. These options may be fully exercised if employment is terminated for 'good reason' or without 'cause' within one year of a change in control event. Karyopharm focuses on developing novel cancer therapies, including its lead drug, XPOVIO®.
Karyopharm Therapeutics (Nasdaq: KPTI) reported first-quarter 2021 results, showing a net product revenue of $21.7 million, up 35% year-over-year. The company highlighted a leadership transition with Richard Paulson appointed as the new CEO. The ongoing U.S. commercialization of XPOVIO reflects a significant increase in prescription demand, with approximately 1,170 prescriptions filled, marking a 17% increase from Q4 2020. Karyopharm anticipates top-line data from the Phase 3 SIENDO study by year-end and expects a decision from the European Commission on NEXPOVIO in Q4 2021.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) appointed Richard Paulson as President and Chief Executive Officer effective May 3, 2021, succeeding Michael G. Kauffman and Sharon Shacham. Paulson, who has extensive biopharmaceutical experience and previously served as CEO of Ipsen North America, aims to enhance Karyopharm's commercialization efforts and expand the reach of its lead product, XPOVIO. Kauffman transitions to Senior Clinical Advisor, focusing on clinical developments. The leadership change is positioned as essential for driving growth and innovation at a pivotal moment for the company.
Karyopharm Therapeutics (NASDAQ:KPTI) will report its first quarter 2021 financial results on May 3, 2021. The company's management will host a conference call at 8:30 a.m. ET on the same day to discuss the results and provide updates. Karyopharm is known for its innovative cancer therapies, particularly its lead compound, XPOVIO (selinexor), which is approved for multiple indications and has received conditional marketing authorization in Europe.
Karyopharm Therapeutics (Nasdaq: KPTI) has announced the validation of its Type II Variation Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for NEXPOVIO® (selinexor). This application aims to expand the use of NEXPOVIO in combination with Velcade® and low-dose dexamethasone for treating adult patients with multiple myeloma who have undergone at least one prior therapy. The decision is based on encouraging results from the Phase 3 BOSTON study. The EMA's review is expected to conclude in Q4 2021, signifying a vital step in enhancing treatment options for multiple myeloma in Europe.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the publication of health-related quality of life (HRQoL) data from the Phase 3 SEAL study, evaluating selinexor in advanced unresectable dedifferentiated liposarcoma (DDLPS). The study showed a statistically significant improvement in progression-free survival (PFS) and notable reductions in pain for patients treated with selinexor compared to placebo. With 285 patients involved, the results underscore selinexor's potential to provide meaningful clinical benefits, despite being unapproved for DDLPS. Adverse effects included manageable cytopenias and gastrointestinal issues.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options for 150,600 shares to 15 new employees, effective March 31, 2021. The options have an exercise price of $10.52, aligning with the closing price on the grant date. These options will vest over four years, with an initial 25% vesting after one year, followed by monthly vesting. Additionally, the options may become fully exercisable upon termination for 'good reason' or without 'cause' after a 'change in control' event. This move is expected to attract talent as the company advances its cancer therapies.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that the European Commission has granted conditional marketing authorization for NEXPOVIO (selinexor) in combination with dexamethasone for treating adult patients with heavily pretreated multiple myeloma. This breakthrough therapy targets patients who have undergone at least four prior treatments and are refractory to multiple other therapies. The authorization is based on positive results from the Phase 2b STORM study, which showed a 26% overall response rate. The drug is the first nuclear export inhibitor approved in Europe and is set for initial availability through a Named Patient Program.